Race To Build Zinbryta's MS Market Share Ahead Of Even More Competition
New multiple sclerosis drug Zinbryta adds a European approval to its regulatory status, but is targeting a market where there are already various options for treating relapsing-remitting MS patients.
You may also be interested in...
Antibody was approved in the US with a liver safety warning while EU regulators recently limited the drug's use. Now, EMA has begun an urgent review of reports of inflammatory brain disorders related to Zinbryta.
Biogen Inc. and AbbVie Inc. may have won the FDA's approval to market Zinbryta (daclizumab) as a treatment for multiple sclerosis, but the firms are facing significant barriers in marketing the drug, which is entering an already crowded field and coming to the marketplace with a black-box warning about serious adverse liver risks, limiting its sales potential.
Biogen and AbbVie Inc.'s multiple sclerosis therapy, Zinbryta (daclizumab), has been given a green light for use in Europe – but what gap can this new drug fill in a crowded therapy space?